XW03306 Introduction of Brexanolone into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW03308 Introduction of Spesolimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW0332 Nerinitide
XW03326 Introduction of Nerinitide into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW0333 Durvalumab Antineoplastic
XW03336 Introduction of Durvalumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW0333A Introduction of Bentracimab, Ticagrelor Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW0334 Cefepime-taniborbactam Anti-infective
XW0334A Introduction of Cefepime-taniborbactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW0335 Narsoplimab Monoclonal Antibody
XW03357 Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW03358 Introduction of Mosunetuzumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW0335A Introduction of Ceftobiprole Medocaril Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW0336 Lefamulin Anti-infective
XW03366 Introduction of Lefamulin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW03367 Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW03368 Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW0337 Coagulation Factor Xa, Inactivated
XW03372 Introduction of Inactivated Coagulation Factor Xa into Peripheral Vein, Percutaneous Approach, New Technology Group 2
XW03377 Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW03378 Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW0338 Lurbinectedin
XW03387 Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW03388 Introduction of Treosulfan into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW0338A Introduction of Obecabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW0339 Ceftolozane/Tazobactam Anti-infective
XW03396 Introduction of Ceftolozane/Tazobactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW03398 Introduction of Inebilizumab-cdon into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW0339A Introduction of Odronextamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW033A Cefiderocol Anti-infective
XW033A6 Introduction of Cefiderocol Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033A7 Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033B Cytarabine and Daunorubicin Liposome Antineoplastic
XW033B3 Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3
XW033B6 Introduction of Omadacycline Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033B7 Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033BA Introduction of Orca-T Allogeneic T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW033C Eculizumab
XW033C6 Introduction of Eculizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033C7 Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033CA Introduction of Zanidatamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW033D Atezolizumab Antineoplastic
XW033D6 Introduction of Atezolizumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033DA Introduction of Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW033E Remdesivir Anti-infective
XW033E5 Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033E6 Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033F Other New Technology Therapeutic Substance
XW033F3 Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 3
XW033F5 Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033F6 Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033FA Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW033G Sarilumab
XW033G5 Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033G6 Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033G7 Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033H Tocilizumab
XW033H5 Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033H6 Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033H7 Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033J Tisagenlecleucel Immunotherapy
XW033J7 Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033K Idecabtagene Vicleucel Immunotherapy
XW033K7 Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033K9 Introduction of Sulbactam-Durlobactam into Peripheral Vein, Percutaneous Approach, New Technology Group 9
XW033L CD24Fc Immunomodulator
XW033L6 Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033L7 Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033M Brexucabtagene Autoleucel Immunotherapy
XW033M7 Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033N Lisocabtagene Maraleucel Immunotherapy
XW033N7 Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033P Glofitamab Antineoplastic
XW033P9 Introduction of Glofitamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 9
XW033Q Tagraxofusp-erzs Antineoplastic
XW033Q5 Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033Q9 Introduction of Posoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 9
XW033R Rezafungin
XW033R9 Introduction of Rezafungin into Peripheral Vein, Percutaneous Approach, New Technology Group 9
XW033S Iobenguane I-131 Antineoplastic
XW033S5 Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033W Caplacizumab
XW033W5 Introduction of Caplacizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5